Swiss PharmaCan starts clinical study on long Covid
Frauenfeld - Swiss PharmaCan has started a clinical study to confirm the effectiveness of ArtemiC Support against long Covid. The study is being conducted in Barcelona with support from Glow LifeTech in Canada and MGC Pharmaceuticals in Australia as partners.
Swiss PharmaCan has announced the launch of a clinical study to confirm the effectiveness of ArtemiC Support in patients with long Covid. According to a press release from the company based in the St.GallenBodenseeArea, the study includes 150 adults suffering from long Covid. It will be carried out in Barcelona, Spain. Authorization was granted by the Catalan Health Authority. The first patient reportedly began treatment with ArtemiC Support on 15 December. Patients will take five drops of ArtemiC Support three times daily for a total of six weeks.
“The use of ArtemiC Support has shown clear improvement of long Covid symptoms after just a few days,” said research collaborator Dr. Francisco Mera Cordero from the Catalan Health Authority DAP Costa de Ponent. Long Covid patients “are severely debilitated and can suffer from neurological symptoms – Paresthesia, Dysesthesia, pins and needles in the face, arms or legs, lack of energy, a lot of fatigue and even breathing problems,” added Mera Cordero.
Swiss PharmaCan is conducting this trial to determine the treatment potential of ArtemiC Support with co-sponsors Glow LifeTech in Canada and MGC Pharmaceuticals in Australia. The study will be conducted in Spain at the Medical Research Center EAP Sardenya in cooperation with UniversalDoctor from Barcelona. This follows the successful completion of a Phase II clinical trial on 50 patients with COVID-19.
ArtemiC Support is a clinically tested food supplement containing three naturally derived ingredients, which is available worldwide without prescription. MyCell Technology encapsulates these active ingredients and enables safe and efficient absorption by human cells.